Stocks Thread

**Kamal** · November 20, 2020, 10:46:05 AM

Re: Stocks Thread

Not a day trader but due to the market crash in Feb this year, I signed up for an account on Robinhood and traded some shipping stocks.

**REDROCK** · November 20, 2020, 06:14:32 PM

Re: Stocks Thread

Shipping stocks have been interesting to me, I haven't pulled the trigger on any of them though. Which ones have been good to you Kamal?

Currently mostly invested in DNK - made a good return on NAKD, but my long investment has been VXRT. RH is cool, because it's easy, but Webull has more detailed info.

**Kamal** · November 25, 2020, 10:50:29 AM

Re: Stocks Thread

deleted

**floridaorange** · November 25, 2020, 10:42:44 PM

Re: Stocks Thread

Nice work!!

**floridaorange** · November 29, 2020, 09:35:58 AM

Re: Stocks Thread

Went in big (for me) on IDEX. Will swing trade it this week and then hopefully move earnings over to VXRT if i can get it sub $8.

**i!!ustrious** · December 15, 2020, 09:49:22 PM

Re: Stocks Thread

cheers bretheren may we sumday have a yacht flotilla ms

**floridaorange** · December 23, 2020, 03:43:24 PM

Re: Stocks Thread

Doing very well with OCGN - Kamal - what do your pals in India tell you

Is Ocugen Stock Still Worth Buying After Its 800%-Plus Rally? Analyst Weighs In

https://finance.yahoo.com/news/ocugen-stock-still-worth-buying-165832224.html

Can you feel the ground moving beneath your feet? Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market.Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway.The agreement stipulates Ocugen will hold the vaccine’s U.S. rights, and the remaining details are expected to be finalized over the coming weeks.Considering Bharat’s reputation for world-class R&D and manufacturing capabilities in vaccines and bio-therapeutics, H.C. Wainwright analyst Swayampakula Ramakanth thinks the company is a “suitable partner.”Ramakanth believes the “broad immunity targeting different components of the virus could potentially provide better protection against emerging mutant viruses, such as the one currently circulating in the UK.” With this in mind, in the Phase 1 study, COVAXIN has shown robust antibody responses against spike (S1) protein, receptor-binding domain (RBD) and the nucleocapsid (N) protein of SARS-CoV-2. “More importantly,” the 5-star analyst added, “COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.”Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXIN’s development.However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of “insight into the U.S. regulatory pathway or commercial strategy,” Ramakanth stays on the sidelines for now.Accordingly, the analyst rates OCGN a Neutral (i.e. Hold) without suggesting a price target. (To watch Ramakanth’s track record, click here)In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. However, the Strong Buy consensus rating is backed with a $0.9 price target, which implies downside of 68% from current levels. This is most likely a result of the stock’s meteoric rise and analysts’ inability to turnaround new price targets so quickly. (See OCGN stock analysis on TipRanks)To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

**floridaorange** · January 2, 2021, 12:31:18 PM

Re: Stocks Thread

Great news India! OCGN!

The Subject Expert Committee (SEC) of Central Drugs Standards Control Organisation (CDSCO) makes recommendations in respect of Accelerated Approval Process request of M/s Serum Institute of India and M/s Bharat Biotech International Ltd as well as about Phase-III Trials of M/s Cadila Healthcare Ltd

https://pib.gov.in/PressReleseDetailm.aspx?PRID=1685678

The Subject Expert Committee of CDSCO met on 1st and 2nd January, 2021 and made the following recomm

**Kamal** · January 4, 2021, 11:08:46 AM

Re: Stocks Thread

Originally posted by floridaorange

Doing very well with OCGN - Kamal - what do your pals in India tell you

https://finance.yahoo.com/news/ocuge...165832224.html

Just saw this, I haven't heard much of it to be honest. I don't follow much of what is going on back home other than with family and friends.

**floridaorange** · January 5, 2021, 06:47:17 PM

Re: Stocks Thread

Made a great return on ocgn, took earnings to jagx and chek before they shot up yesterday. great start to the yr

**dusk** · February 16, 2021, 12:34:45 PM

Re: Stocks Thread

Good going florida... I think I may finally get into some long term stocks... waited far to long to get into this game.

**Kamal** · February 16, 2021, 12:42:22 PM

Re: Stocks Thread

If you want to invest in a safe portfolio, try Acorns. They're pretty good and their portfolios have a decent rate of return

**dusk** · February 16, 2021, 12:52:03 PM

Re: Stocks Thread

Thanks K! Will check it out.

**floridaorange** · February 17, 2021, 07:27:51 AM

Re: Stocks Thread

SOS & CNET both being very good to me...

Stocks Thread

Stocks Thread

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment